Document Detail

Enhanced ferritin/iron ratio in psoriasis.
Jump to Full Text
MedLine Citation:
PMID:  22771596     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND & OBJECTIVES: Psoriasis is a chronic, recurrent skin disorder, with a poorly understood pathogenesis. Studies at molecular/genetic levels continue to explore various biomolecules as potential markers of the disease. In the present study, we sought to evaluate the possible roles of ferritin and iron in psoriasis.
METHODS: Patients with psoriasis (n=81) and healthy controls (n=45) were included. Patients were graded as mild, moderate and severe based on the Psoriasis Area Severity Index (PASI). Serum ferritin and iron levels were measured by electro chemiluminescence and inductively coupled plasma - atomic emission spectrometry (ICP-AES), respectively.
RESULTS: The ferritin levels in psoriasis patients were not significantly different from that of controls. There was no significant difference in ferritin concentrations between psoriasis groups of severity. Fe was found to be significantly reduced (P<0.05) in the psoriasis patients when compared to controls. The ferritin to Fe ratio was significantly higher (P<0.05) in the psoriasis groups when compared to the control group.
INTERPRETATION & CONCLUSIONS: Our results indicate a possible role of ferritin and iron in psoriasis. Further studies with large samples need to be done to confirm findings.
Authors:
R Rashmi; A M Yuti; K H Basavaraj
Related Documents :
10913986 - Transnasal gastroscopy.
2792656 - Manometric responses to balloon distention in patients with nonobstructive dysphagia.
3783366 - Abnormal tracheal innervation in patients with esophageal atresia and tracheoesophageal...
829076 - Chagas' megaesophagus: manometric studies before and after thal's fundic patch operation.
24681036 - Nonspecific pleuritis: optimal duration of follow-up.
22336636 - Ischemia modified albumin: an oxidative stress marker in β-thalassemia major.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Indian journal of medical research     Volume:  135     ISSN:  0971-5916     ISO Abbreviation:  Indian J. Med. Res.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-07-09     Completed Date:  2012-12-31     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  0374701     Medline TA:  Indian J Med Res     Country:  India    
Other Details:
Languages:  eng     Pagination:  662-5     Citation Subset:  IM    
Affiliation:
Department of Dermatology, JSS Medical College, JSS University, Mysore, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Child
Female
Ferritins / blood*
Humans
Iron / blood*
Luminescent Measurements
Male
Middle Aged
Psoriasis / blood*,  pathology
Spectrophotometry, Atomic
Chemical
Reg. No./Substance:
7439-89-6/Iron; 9007-73-2/Ferritins
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Indian J Med Res
Journal ID (iso-abbrev): Indian J. Med. Res
Journal ID (publisher-id): IJMR
ISSN: 0971-5916
Publisher: Medknow Publications & Media Pvt Ltd, India
Article Information
Download PDF
Copyright: © The Indian Journal of Medical Research
open-access:
Accepted Day: 26 Month: 8 Year: 2010
Print publication date: Month: 5 Year: 2012
Volume: 135 Issue: 5
First Page: 662 Last Page: 665
ID: 3401697
PubMed Id: 22771596
Publisher Id: IJMR-135-662

Enhanced ferritin/iron ratio in psoriasis
R. Rashmiaff1
A.M. Yutiaff1
K.H. Basavarajaff1
Department of Dermatology, JSS Medical College, JSS University, Mysore, India
Correspondence: Reprint requests: Dr. K.H. Basavaraj, Professor, Department of Dermatology, JSS Medical College, JSS University, Mysore 570 015, India e-mail: basavarajkh@yahoo.co.in

Psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory changes in the epidermis and dermis1. The pathogenesis of this complex, multifactorial disease is incompletely understood. The genetic susceptibility and involvement of the innate immune system in psoriasis have been reported2, 3. The involvement of proinflammatory cytokines, such as interleukins (ILs), tumour necrosis factor (TNF), and interferon-γ (IFN-γ), has been identified in psoriasis4, 5. The worsening of psoriasis has been linked with oxidative stress1. Disorders in the antioxidant defense mechanisms are known to be involved in the pathogenesis of psoriasis6, 7. The Psoriasis Area Severity Index (PASI)8 is a useful tool in monitoring the response of psoriasis to any therapeutic regimen. Besides the use of clinical measures like PASI, attempts have been made to establish markers for psoriasis at both tissue9 and serum levels10, 11.

There is some evidence regarding the roles of various metals and metal binding proteins in psoriasis and possibilities of evaluating these as potential markers of the disease would provide better targets for effective control of the disease. The involvement of trace metals1214 and altered trace metal homeostasis15 in psoriasis has been reported. However, very limited studies have focused on the involvement of metal binding proteins in psoriasis1, 1618. The metalloproteins are known to ameliorate the deleterious effects of the reactive oxygen species (ROS) by binding to the redox active metals like copper (Cu) and iron (Fe), thus minimizing their capacity to catalyze ROS production via the Fenton reaction19. Ferritin is an iron storage protein, the levels of which is known to increase as a result of oxidative stress20 and inflammation21. The role of ferritin in patients with rosacea22 and alopecia23 has been reported. The present study was undertaken to investigate the role of ferritin and iron in psoriasis.


Material & Methods

A total of 81 consecutive patients consulting the Department of Dermatology, JSS Medical College Hospital, Mysore, India, during November 2007 and July 2009 were included in the study. Psoriasis was graded according to the PASI, presenting at the time of blood collection. The patients were divided into three groups based on the severity of the disease as mild (PASI <3), moderate (PASI 3.1-10) and severe (PASI >10). Among the patients, 15 were mild cases, 37 moderate and 29 were severe cases. The age ranged between 9 and 70 yr in the cases. The male : female ratios in the three psoriasis groups were 10 :5, 26 : 11 and 23 :6. Controls were volunteers with no significant illness. The duration of psoriasis varied from 5 days to 15 yr. Persons with history of diabetes, hypertension, psychiatric disorders, cardiac problems and other chronic skin disorders (other than psoriasis) were excluded. The control group consisted of healthy volunteers (n=45) having no significant medical illness (34 men and 11 women). The study protocol was approved by the Research Ethical Committee of J.S.S. Medical College Hospital, Mysore, India. A written consent was obtained from the patients/guardians prior to the collection of blood samples.

Blood (10 ml) was collected under aseptic condition from the cubital fossa using IV cannula with injection port. Blood was allowed to clot at room temperature for about 15 min and centrifuged at 3000 rpm for 20 min to separate the serum. The serum was frozen at -80 °C for subsequent analyses. Serum ferritin was measured by electro chemiluminescence method using automated analyzer (Elecsys 2010). A reference range of 30-340 ng/ml for men and 13-150 ng/mL for women was used. Analysis of serum Fe was carried out using an inductively coupled plasma- atomic emission spectrometry (ICP- AES) model Jobin Yvon 38 sequential analyzer. All dilutions were made with ultra pure milliQ water.

Comparisons between groups of severity were done using one way analysis of variance (ANOVA). Comparisons between the psoriasis and the control groups were done by t test. All statistical analyses were performed using SPSS software for Windows (Version 16.0).


Results & Discussion

The ferritin level in the mild group (50.4 ± 46.24 μg/l) was found to be lower than the control group (77.42 ± 12.42 μg/l). Ferritin level in moderate psoriasis group was found to be slightly higher than the control group (Table). No significant difference was observed between male and female subjects and controls.

When compared with the control group, Fe levels in the psoriasis groups were lower. This decrease was significant in the mild and severe groups (P<0.05). The moderate group showed an insignificant reduction in Fe levels when compared to the controls. The variation in the Fe levels did not present a particular trend in the psoriasis groups of severity. No significant difference was seen in the Fe levels between psoriasis groups. When Fe levels of all the psoriasis patients (1.1 ± 0.04 μg/ml) was compared with the controls, a significant difference (P <0.05) was observed (Table).

In order to address disequilibrium between ferritin and Fe in psoriasis, the ratio of ferritin to Fe was computed and compared. The ferritin : Fe ratios in the mild, moderate and severe groups were 0.05 ± 0.007, 0.07 ± 0.017 and 0.08 ± 0.022, respectively. Though the ratio appeared to increase with groups of severity, the increase was not significant. When compared to the control group (0.02 ± 0.04), the psoriasis groups exhibited significantly (P<0.05) higher values of the ratio (Table).

PASI score has been used for the assessment of severity of psoriasis and as a tool to monitor response to treatment. The use of markers in combination with clinical measures like PASI will help in better understanding the disease as well as to develop treatment strategies and monitor responses. Serum markers like cytokines have been instrumental in understanding the pathology of skin diseases like psoriasis. The presence of excess Fe has been demonstrated in many skin diseases involving an inflammatory response including psoriasis24, 25. In psoriasis, low serum Fe levels have been reported15. There are a few studies describing the role of transferrin and transferrin receptors in psoriasis1, 26.

Ferritin is known to be a proven marker of iron status27, 28. Blood ferritin concentration is a biomarker of iron storage29. Ferritin and iron homeostasis is implicated in the pathogenesis of many disorders, including diseases involved in iron acquisition, transport and storage as well as in atherosclerosis, Parkinson's disease, Alzheimer disease and restless leg syndrome30. Serum ferritin protein is an acute phase reactant and apoferritin is known to be raised in conditions such as inflammation21 and infection31. During acute phase response, IL-1β and TNF-α have been shown to influence the expression of ferritin21.

Accelerated loss of nutrients from the hyperproliferation and desquamation of the epidermal layer of skin in psoriasis has been reported32. It can be speculated that Fe may be lost due to desquamation resulting in reduced ferritin levels in psoriasis. Fe is an important requirement of cell division. Increased utilization of Fe by the proliferating cells may also result in reduced levels of ferritin in psoriasis. Our results are in contradiction with other studies reporting an increased ferritin expression due to inflammation21, 33. It is established that severe psoriasis may lead to nutrient depletion as reflected by the decreased haematocrit32. Our study reveals a significant reduction in the Fe levels in the serum of psoriasis patients. However, we have not evaluated tissue levels of Fe. A higher Fe level has been reported in the dermis of psoriasis patients when compared to controls24. Psoriatic arthritis cases were not included in our study. Further, we analysed the total Fe (bound and unbound) in the serum samples. These could be the reasons for difference in findings. However, our data on ferritin in psoriasis patients remained insignificant. Studies engaging larger patient groups may provide a better picture of whether or not ferritin has a role to play in the disease pathogenesis. It would be interesting to study the variations of both ferritin and Fe at tissue and serum levels and their correlation.

In order to understand the effect of ferritin on psoriasis severity, we calculated the ratio of ferritin to Fe in all psoriasis patients. We observed a significant increase in the Ferritin-Fe ratio in the psoriasis groups compared to controls. Further, an increasing trend in the ratio was seen between groups of severity though our results were not significant. Despite the diminished systemic Fe levels the ferritin levels were not reduced because inflammation induces a ferritin response in active psoriasis. This inflammation-related ferritin induction might increase with psoriasis disease severity leading to a tendency in increasing ferritin/Fe ratio. The ratio describes the effect of non-ferritin iron in psoriasis and probably this would distinguish subjects as mild, moderate or severe. However, in the representative population of 81 psoriasis patients, this finding was not significant.

We have not measured markers of inflammation such as proinflammatory cytokines like TNF-α and their possible effects on the expression of ferritin. Interpreting ferritin along with inflammatory markers in psoriasis may explain its role in psoriasis better. Although the importance of measurement of metals and metal binding proteins in psoriasis is evident from our results, the levels of Fe and ferritin did not prove to be useful in assessing severity of psoriasis. The ratio of ferritin to Fe may be useful in assessing psoriasis severity. However, larger study groups are needed to validate the appropriateness of these findings. Further studies correlating both tissue and serum levels of ferritin are needed to understand at what level ferritin may be involved in the pathogenesis of psoriasis. Our results suggest that larger prospective studies are required to evaluate the role of serum ferritin in psoriasis.


Acknowledgment

The work was supported by a research grant from the Department of Biotechnology, New Delhi, India. Authors thank Prof. Suresh, Vice Chancellor, JSS University, Mysore for his encouragement, and Principal, JSS Medical College, for his support.


References
1. Rocha-Pereira P,Santos-Silva A,Rebelo I,Figueiredo A,Quintanilha A,Teixeira F. The inflammatory response in mild and in severe psoriasisBr J DermatolYear: 20041509172815149504
2. Elder JT,Bruce AT,Gudjonsson JE,Johnston A,Stuart PE,Tejasvi T,et al. Molecular dissection of psoriasis: integrating genetics and biologyJ Invest DermatolYear: 201013012132619812592
3. Lowes MA,Bowcock AM,Krueger JG. Pathogenesis and therapy of psoriasisNatureYear: 20074458667317314973
4. Nestle FO,Kaplan DH,Barker J. PsoriasisN Engl J MedYear: 200936149650919641206
5. Nickoloff BJ,Xin H,Nestle FO,Qin JZ. The cytokine and chemokine network in psoriasisClin DermatolYear: 2007255687318021894
6. Wozniak A,Drewa G,Krzyzynska-Maliniowska E,Czajkowski R,Protas-Drozdf,Mila-Kierzenkowska C,et al. Oxidant-antioxidant balance in patients with psoriasisMed Sci MonitYear: 200713CR30317179907
7. Zhou Q,Mrowietz U,Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasisFree Radic Biol MedYear: 20094789190519577640
8. Fredriksson T,Pettersson U. Severe psoriasis: Oral therapy with a new retinoidDermatologicaYear: 197815723844357213
9. Saraceno R,Kleyn CE,Terenghi G,Griffiths CE. The role of neuropeptides in psoriasisBr J DermatolYear: 20061558768217034513
10. Flisiak I,Zaniewski P,Chodynicka B. Plasma TGF-beta1, TIMP-1, MMP-1 and IL-18 as a combined biomarker of psoriasis activityBiomarkersYear: 2008135495618979644
11. Gerdes S,Kurrat W,Mrowietz U. Serum mast cell tryptase is not a useful marker for disease severity in psoriasis or atopic dermatitisBr J DermatolYear: 20091607364019076976
12. Greaves MW. Zinc and copper in psoriasisBr J DermatolYear: 19718417895548468
13. Hinks LJ,Young S,Clayton B. Trace element status in eczema and psoriasisClin Exp DermatolYear: 1987129373677478
14. Smith SA,Aamir F,Otis MP. Elevated serum nickel concentration in psoriasis vulgarisInt J DermatolYear: 19943378357822082
15. Basavaraj KH,Darshan MS,Shanmugavelu P,Rashmi R,Mhatre AY,Dhanabal SP,et al. Study on the levels of trace elements in mild and severe psoriasisClin Chim ActaYear: 2009405667019383492
16. Grigorian VA,Karagezian KG,Babaian KR,Simonian MA,Badalian MA,Obejan GA,et al. Blood metalloproteins of pro-oxidant and antioxidant action in psoriasisUkr Biokhim ZhYear: 1998701495210445277
17. Lal S,Rajagopal G,Subrahmanyam K. Serum caeruloplasmin in psoriasisIndian J DermatolYear: 19711610345120658
18. Stratigos J,Kasimatis B,Panas E,Capetanakis J. The biochemistry of psoriasis.Serum copper and ceruloplasmin in psoriasis patientsAnn Dermatol Syphiligr (Paris)Year: 197610358471015800
19. Levy MA,Tsai YH,Reaume A,Bray TM. Cellular response of antioxidant metalloproteins in Cu/Zn SOD transgenic mice exposed to hyperoxiaAm J Physiol Lung Cell Mol PhysiolYear: 2001281L1728211404260
20. Orino K,Lehman L,Tsuji Y,Ayaki H,Torti SV,Torti FM. Ferritin and the response to oxidative stressBiochem JYear: 2001357241711415455
21. Kalantar-Zadeh K,Rodriguez RA,Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patientsNephrol Dial TransplantYear: 200419141914671049
22. Tisma VS,Basta-Juzbasic A,Jaganjac M,Brcic L,Dobric I,Lipozencic J,et al. Oxidative stress and ferritin expression in the skin of patients with rosaceaJ Am Acad DermatolYear: 200960270619028405
23. Kantor J,Kessler LJ,Brooks DG,Cotsarelis G. Decreased serum ferritin is associated with alopecia in womenJ Invest DermatolYear: 2003121985814708596
24. Leveque N,Robin S,Muret P,Mac-Mary S,Makki S,Berthelot A,et al. In vivo assessment of iron and ascorbic acid in psoriatic dermisActa Derm VenereolYear: 2004842515040469
25. Molin L,Wester PO. Iron content in normal and psoriasis epidermisActa Dermato VenerealYear: 1973534736
26. Iwata M,Otsuka F,Watanabe S,Nogita T,Ishibashi Y. Expression of transferrin receptor in normal human skin, psoriatic skin and various skin tumorsJ DermatolYear: 198815208113053829
27. Aimone-Gastin I. Biochemical markers of iron statusNephrol TherYear: 20062S321617373277
28. Vernet M. Assessment of iron statusRev PratYear: 200050950610865492
29. Mburu AS,Thurnham DI,Mwaniki DL. The influence and benefits of controlling for inflammation on plasma ferritin and hemoglobin responses following a multi-micronutrient supplement in apparently healthy, HIV+ Kenyan adultsJ NutrYear: 2008138613918287375
30. Zandman-Goddard G,Shoenfeld Y. Hyperferritinemia in autoimmunityIsr Med Assoc JYear: 20081083418300583
31. Birgegård G,Hällgren R,Killander A,Strömberg A,Venge P,Wide L. Serum ferritin during infection-A longitudinal studyScand J HematolYear: 19782133340
32. Prystowsky JH,Orologa A,Taylor S. Update on nutrition and psoriasisInt J DermatolYear: 19933258268407074
33. Waheed P,Naveed AK,Farooq F. Levels of inflammatory markers and their correlation with dyslipidemia in diabeticsJ Coll Physicians Surg PakYear: 2009192071019356332

Tables
[TableWrap ID: T1] Table 1 

Ferritin and iron (Fe) levels in psoriasis patients and controls




Article Categories:
  • Original Article

Keywords: Ferritin, ferritin iron ratio, iron, psoriasis, Psoriasis Area Severity Index.

Previous Document:  Effects of infliximab on bacterial translocation in experimental acute necrotizing pancreatitis.
Next Document:  Heat stable antimicrobial activity of Burkholderia gladioli OR1 against clinical drug resistant isol...